Gelteq GELS
NASDAQ GELS
$0.42 -0.03 (-6.12%)
At close: Nov 10, 2026 · 4:00 PM EST

Gelteq (GELS) Total Current Liabilities (2023 - 2025)

Updated

Gelteq (GELS) recorded Total Current Liabilities of $3.86 million in the quarter ended Dec 31, 2025, down 6.1% from $4.11 million a year earlier.

Analysis

Gelteq (GELS) Total Current Liabilities (2023 - 2025) Analysis & Trends

As of Jun 30, 2025, Gelteq reported Total Current Liabilities of $3.61 million, up 41.6% from the prior year.

  • Across earlier years, Total Current Liabilities came in at $2.55 million in the year ended Jun 30, 2024 (+179.4%) and $911,995 in the year ended Jun 30, 2023.
  • Quarterly Total Current Liabilities has ranged from $911,995 in the quarter ended Jun 30, 2023 to $4.11 million in the quarter ended Dec 31, 2024 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Iqvia Holdings 45.39 Bn 36.65 Bn 1.50 Bn 7.78 Bn
2 Medpace Holdings 18.59 Bn 16.24 Bn 223.89 Mn 1.50 Bn
3 Charles River Laboratories International 16.59 Bn 15.79 Bn 357.87 Mn 1.09 Bn
4 Icon 15.81 Bn 12.58 Bn 491.83 Mn 2.77 Bn
5 Fortrea Holdings 2.06 Bn 1.35 Bn 139.50 Mn 983.30 Mn
6 Ginkgo Bioworks Holdings 758.79 Mn -3.29 Mn 18.44 Mn 72.74 Mn
7 Evotec SE 603.77 Mn -1.27 Bn - 432.39 Mn
8 Champions Oncology 68.48 Mn 44.13 Mn 7.70 Mn 18.73 Mn
9 MindWalk Holdings 48.71 Mn 12.36 Mn 1.61 Mn 4.74 Mn
10 Gelteq 4.07 Mn 1.92 Mn - 3.93 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 3.93 Mn
Jun 30, 2025 3.68 Mn
Dec 31, 2024 3.91 Mn
Jun 30, 2024 2.57 Mn
Jun 30, 2023 903,276.10
API Access

Gelteq Total Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-current-liabilities&ticker=GELS&period=max&api_key=YOUR_API_KEY